| 1 | The importance of viruses in ventilator-associated pneumonia | 2.3 | 9 | Citations (PDF) |
| 2 | Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study | 1.8 | 2 | Citations (PDF) |
| 3 | Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock | 4.1 | 3 | Citations (PDF) |
| 4 | Race Does Not Impact Sepsis Outcomes When Considering Socioeconomic Factors in Multilevel Modeling | 0.6 | 13 | Citations (PDF) |
| 5 | Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method | 8.9 | 18 | Citations (PDF) |
| 6 | Prospective Nasal Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> in Critically Ill Patients With Suspected Pneumonia | 0.8 | 11 | Citations (PDF) |
| 7 | Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia | 3.2 | 17 | Citations (PDF) |
| 8 | Classical and Molecular Techniques to Diagnose HAP/VAP | 2.3 | 4 | Citations (PDF) |
| 9 | Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study | 0.7 | 3 | Citations (PDF) |
| 10 | How to use new antibiotics in the therapy of ventilator-associated pneumonia | 3.6 | 1 | Citations (PDF) |
| 11 | Mechanical Ventilation Practices and Low Tidal Volume Ventilation in Air Medical Transport Patients: The AIR-VENT Study | 1.5 | 3 | Citations (PDF) |
| 12 | Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia | 1.3 | 3 | Citations (PDF) |
| 13 | β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value 2022, 4, e0726 | | 22 | Citations (PDF) |
| 14 | Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumonia | 0.7 | 1 | Citations (PDF) |
| 15 | Next Steps in Pneumonia Severity Scores | 5.6 | 4 | Citations (PDF) |
| 16 | Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial | 8.9 | 394 | Citations (PDF) |
| 17 | Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia | 4.3 | 4 | Citations (PDF) |
| 18 | Racial Disparities in Readmissions Following Initial Hospitalization for Sepsis | 0.6 | 19 | Citations (PDF) |
| 19 | Nosocomial Infection | 0.6 | 164 | Citations (PDF) |
| 20 | Pneumococal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance | 2.7 | 8 | Citations (PDF) |
| 21 | Comparison of Sepsis Definitions as Automated Criteria | 0.6 | 26 | Citations (PDF) |
| 22 | Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical Care 2021, 3, e0468 | | 22 | Citations (PDF) |
| 23 | A Pragmatic Machine Learning Model To Predict Carbapenem Resistance | 4.3 | 28 | Citations (PDF) |
| 24 | New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam | 4.3 | 34 | Citations (PDF) |
| 25 | Initial antimicrobial management of sepsis | 7.4 | 130 | Citations (PDF) |
| 26 | Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial | 7.4 | 29 | Citations (PDF) |
| 27 | Monoclonal antibodies as antibacterial therapies: thinking outside of the box | 8.9 | 13 | Citations (PDF) |
| 28 | Spot the difference: comparing results of analyses from real patient data and synthetic derivatives | 3.0 | 59 | Citations (PDF) |
| 29 | Timing of antibiotic therapy in the ICU | 7.4 | 121 | Citations (PDF) |
| 30 | Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial | 7.4 | 17 | Citations (PDF) |
| 31 | Short- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study | 2.7 | 2 | Citations (PDF) |
| 32 | The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An UpdateDrugs, 2021, 81, 2117-2131 | 9.1 | 528 | Citations (PDF) |
| 33 | Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study | 0.8 | 21 | Citations (PDF) |
| 34 | Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill | 5.6 | 4 | Citations (PDF) |
| 35 | Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia – Authors' reply | 8.9 | 0 | Citations (PDF) |
| 36 | Impact of Baseline Characteristics on Future Episodes of Bloodstream Infections: Multistate Model in Septic Patients With Bloodstream Infections | 5.6 | 5 | Citations (PDF) |
| 37 | Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc | 5.6 | 1 | Citations (PDF) |
| 38 | Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial | 4.4 | 5 | Citations (PDF) |
| 39 | A PRAGMATIC MACHINE LEARNING MODEL TO PREDICT CARBAPENEM RESISTANCE | 0.5 | 1 | Citations (PDF) |
| 40 | Culture-negative sepsis | 3.6 | 32 | Citations (PDF) |
| 41 | Bacterial and fungal superinfections in critically ill patients with COVID-19 | 5.3 | 96 | Citations (PDF) |
| 42 | Limitations of Registration Trials for Nosocomial Pneumonia | 5.6 | 2 | Citations (PDF) |
| 43 | Pulmonary infections complicating ARDS | 5.3 | 125 | Citations (PDF) |
| 44 | Characteristics and outcomes among a hospitalized patient cohort with Streptococcus pneumoniae infection | 1.3 | 6 | Citations (PDF) |
| 45 | Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant RecipientsChest, 2020, 158, 1385-1396 | 0.5 | 12 | Citations (PDF) |
| 46 | Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017 | 7.3 | 745 | Citations (PDF) |
| 47 | PROPHETICChest, 2020, 158, 2370-2380 | 0.5 | 27 | Citations (PDF) |
| 48 | Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill | 2.3 | 10 | Citations (PDF) |
| 49 | 1477. Impact Of Resistance Thresholds On Mortality In Hospital-Acquired And Ventilator-Associated Pneumonia | 0.8 | 0 | Citations (PDF) |
| 50 | Pathogen-Negative Sepsis—An Opportunity for Antimicrobial Stewardship | 0.8 | 12 | Citations (PDF) |
| 51 | Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial | 8.9 | 279 | Citations (PDF) |
| 52 | Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia | 2.7 | 9 | Citations (PDF) |
| 53 | Redefining the Threshold for Broad-Spectrum Antibiotics | 3.7 | 0 | Citations (PDF) |
| 54 | Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit | 2.3 | 13 | Citations (PDF) |
| 55 | Challenges in severe community-acquired pneumonia: a point-of-view review | 5.3 | 145 | Citations (PDF) |
| 56 | Rebuttal From Drs Aguilar and KollefChest, 2019, 155, 668-669 | 0.5 | 0 | Citations (PDF) |
| 57 | Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation | 2.3 | 4 | Citations (PDF) |
| 58 | POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? YesChest, 2019, 155, 662-665 | 0.5 | 5 | Citations (PDF) |
| 59 | Clinical Effect of Expedited Pathogen Identification and Susceptibility Testing for Gram-Negative Bacteremia and Candidemia by Use of the Accelerate PhenoTM System | 1.4 | 21 | Citations (PDF) |
| 60 | Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials | 5.6 | 41 | Citations (PDF) |
| 61 | Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem | 4.3 | 68 | Citations (PDF) |
| 62 | Moving the Practice of Respiratory Therapy Forward | 1.5 | 2 | Citations (PDF) |
| 63 | Early Palliative Care Consultation in the Medical ICU: A Cluster Randomized Crossover Trial | 0.6 | 136 | Citations (PDF) |
| 64 | Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections | 1.3 | 21 | Citations (PDF) |
| 65 | Re-estimating annual deaths due to multidrug-resistant organism infections | 2.3 | 105 | Citations (PDF) |
| 66 | Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia | 0.5 | 41 | Citations (PDF) |
| 67 | Postoperative Pneumonia Prevention in Pulmonary Resections: A Feasibility Pilot Study | 1.8 | 10 | Citations (PDF) |
| 68 | Rationalizing antimicrobial therapy in the ICU: a narrative review | 5.3 | 202 | Citations (PDF) |
| 69 | New antibiotics for community-acquired pneumonia | 3.6 | 37 | Citations (PDF) |
| 70 | Antibiotic Thresholds for Sepsis and Septic Shock | 5.6 | 4 | Citations (PDF) |
| 71 | A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia | 4.3 | 21 | Citations (PDF) |
| 72 | Duration of Exposure to Antipseudomonal β‐Lactam Antibiotics in the Critically Ill and Development of New Resistance | 3.2 | 164 | Citations (PDF) |
| 73 | 2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP) | 0.8 | 0 | Citations (PDF) |
| 74 | Reply to MacFadden et al | 5.6 | 0 | Citations (PDF) |
| 75 | Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality* | 0.6 | 126 | Citations (PDF) |
| 76 | Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis | 4.3 | 27 | Citations (PDF) |
| 77 | Treatment of severe skin and soft tissue infections: a review | 3.6 | 46 | Citations (PDF) |
| 78 | Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection | 2.3 | 23 | Citations (PDF) |
| 79 | Thirty-day hospital readmissions among mechanically ventilated emergency department patients | 0.9 | 7 | Citations (PDF) |
| 80 | The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure | 0.5 | 47 | Citations (PDF) |
| 81 | Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy | 5.6 | 36 | Citations (PDF) |
| 82 | Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease? | 1.5 | 14 | Citations (PDF) |
| 83 | Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections | 0.8 | 80 | Citations (PDF) |
| 84 | Frequent Versus Infrequent Monitoring of Endotracheal Tube Cuff Pressures | 1.5 | 41 | Citations (PDF) |
| 85 | Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia | 4.3 | 11 | Citations (PDF) |
| 86 | qSOFA score: Predictive validity in Enterobacteriaceae bloodstream infections | 2.2 | 10 | Citations (PDF) |
| 87 | Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial | 8.9 | 377 | Citations (PDF) |
| 88 | Monocyte Function and Clinical Outcomes in Febrile and Afebrile Patients With Severe Sepsis | 2.4 | 28 | Citations (PDF) |
| 89 | Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection | 4.3 | 17 | Citations (PDF) |
| 90 | 1008. Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients With Bloodstream Infections | 0.8 | 0 | Citations (PDF) |
| 91 | 2521 Use of forced air warming devices to induce fever-range hyperthermia in critically ill septic patients | 0.6 | 0 | Citations (PDF) |
| 92 | Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection | 1.3 | 39 | Citations (PDF) |
| 93 | 1894. Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians | 0.8 | 0 | Citations (PDF) |
| 94 | 872. PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICU—A Model and Scoring System | 0.8 | 0 | Citations (PDF) |
| 95 | Is Zero Ventilator-Associated Pneumonia Achievable? | 3.8 | 22 | Citations (PDF) |
| 96 | The most recent concepts for the management of bacterial and fungal infections in ICU | 5.3 | 6 | Citations (PDF) |
| 97 | Prevention of hospital-acquired pneumonia | 3.6 | 43 | Citations (PDF) |
| 98 | Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia | 2.7 | 56 | Citations (PDF) |
| 99 | Using wearable technology to predict health outcomes: a literature review | 4.1 | 80 | Citations (PDF) |
| 100 | Differences in mortality between infections due to extended-spectrum-beta-lactamase–producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> | 2.3 | 5 | Citations (PDF) |
| 101 | The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship | 5.3 | 118 | Citations (PDF) |
| 102 | Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial | 4.1 | 101 | Citations (PDF) |
| 103 | Viruses are prevalent in non-ventilated hospital-acquired pneumonia | 2.7 | 73 | Citations (PDF) |
| 104 | COUNTERPOINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? NoChest, 2017, 151, 740-743 | 0.5 | 9 | Citations (PDF) |
| 105 | Rebuttal From Dr KollefChest, 2017, 151, 744-745 | 0.5 | 1 | Citations (PDF) |
| 106 | Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies | 2.3 | 28 | Citations (PDF) |
| 107 | Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Won’t Cut It | 5.6 | 6 | Citations (PDF) |
| 108 | To which extent can we decrease antibiotic duration in critically ill patients? | 3.0 | 10 | Citations (PDF) |
| 109 | Principles of antimicrobial stewardship for bacterial and fungal infections in ICU | 5.3 | 2 | Citations (PDF) |
| 110 | A Prospective One-Year Microbiologic Survey of Combined Pneumonia and Respiratory Failure | 1.3 | 10 | Citations (PDF) |
| 111 | International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia | 7.7 | 1,112 | Citations (PDF) |
| 112 | Controversies and advances in the management of ventilator associated pneumonia | 2.4 | 14 | Citations (PDF) |
| 113 | The author replies | 0.6 | 0 | Citations (PDF) |
| 114 | ICD-9-CM Coding for Multidrug Resistant Infection Correlates Poorly With Microbiologically Confirmed Multidrug Resistant Infection | 2.3 | 8 | Citations (PDF) |
| 115 | CAP, HCAP, HAP, VAPChest, 2017, 152, 909-910 | 0.5 | 10 | Citations (PDF) |
| 116 | Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria | 5.6 | 49 | Citations (PDF) |
| 117 | A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated PneumoniaChest, 2017, 151, 1239-1246 | 0.5 | 159 | Citations (PDF) |
| 118 | Augmented renal clearance is not a risk factor for mortality in Enterobacteriaceae bloodstream infections treated with appropriate empiric antimicrobials | 2.5 | 13 | Citations (PDF) |
| 119 | Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study | 7.4 | 27 | Citations (PDF) |
| 120 | Evaluating the Value of the Respiratory Therapist: Where Is the Evidence? Focus on the Barnes-Jewish Hospital Experience | 1.5 | 25 | Citations (PDF) |
| 121 | The authors reply | 0.6 | 0 | Citations (PDF) |
| 122 | Real‐time automated clinical deterioration alerts predict thirty‐day hospital readmission | 1.4 | 4 | Citations (PDF) |
| 123 | The authors reply | 0.6 | 0 | Citations (PDF) |
| 124 | The Impact of Nighttime Intensivists on Medical Intensive Care Unit Infection-Related Indicators | 2.3 | 5 | Citations (PDF) |
| 125 | In 2035, will all bacteria be multiresistant? Yes | 5.3 | 10 | Citations (PDF) |
| 126 | A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient OutcomesChest, 2016, 150, 1008-1014 | 0.5 | 114 | Citations (PDF) |
| 127 | Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review | 5.3 | 66 | Citations (PDF) |
| 128 | Secular trends in <i>Acinetobacter baumannii</i> resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study | 1.4 | 94 | Citations (PDF) |
| 129 | Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection | 4.3 | 17 | Citations (PDF) |
| 130 | A targeted educational intervention to reduce ventilator-associated complications | 1.5 | 3 | Citations (PDF) |
| 131 | Use of a Shared Canister Protocol for the Delivery of Metered-Dose Inhalers in Mechanically Ventilated Subjects | 1.5 | 5 | Citations (PDF) |
| 132 | Editorial Commentary: Antimicrobial De-escalation: What's in a Name? | 5.6 | 8 | Citations (PDF) |
| 133 | Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients | 2.3 | 25 | Citations (PDF) |
| 134 | <i>Pseudomonas aeruginosa</i>Nosocomial Pneumonia: Impact of Pneumonia Classification | 2.3 | 42 | Citations (PDF) |
| 135 | Targeted Fluid Minimization Following Initial Resuscitation in Septic ShockChest, 2015, 148, 1462-1469 | 0.5 | 78 | Citations (PDF) |
| 136 | Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital ReadmissionChest, 2015, 148, 103-111 | 0.5 | 29 | Citations (PDF) |
| 137 | An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance | 7.4 | 232 | Citations (PDF) |
| 138 | Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship | 7.4 | 36 | Citations (PDF) |
| 139 | Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study | 7.4 | 18 | Citations (PDF) |
| 140 | Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy* | 0.6 | 62 | Citations (PDF) |
| 141 | Risk factors for 30‐day readmission among patients with culture‐positive severe sepsis and septic shock: A retrospective cohort study | 1.4 | 17 | Citations (PDF) |
| 142 | Update on ventilator-associated pneumonia | 3.6 | 26 | Citations (PDF) |
| 143 | Ventilator-Associated PneumoniaChest, 2015, 147, 1448-1450 | 0.5 | 11 | Citations (PDF) |
| 144 | Clinical effectiveness of a sedation protocol minimizing benzodiazepine infusions and favoring early dexmedetomidine: a before-after study | 7.4 | 17 | Citations (PDF) |
| 145 | A Prospective Evaluation of Ventilator-Associated Conditions and Infection-Related Ventilator-Associated Conditions | 0.5 | 114 | Citations (PDF) |
| 146 | Ten old antibiotics that will never disappear | 5.3 | 1 | Citations (PDF) |
| 147 | Surveillance versus clinical adjudication: Differences persist with new ventilator-associated event definition | 1.5 | 15 | Citations (PDF) |
| 148 | The Use of Inhaled Prostaglandins in Patients With ARDSChest, 2015, 147, 1510-1522 | 0.5 | 121 | Citations (PDF) |
| 149 | Ventilator-associated Pneumonia Prevention. Is It Worth It? | 9.3 | 10 | Citations (PDF) |
| 150 | Management of Infections with Drug-Resistant Organisms in Critical Care | 3.8 | 6 | Citations (PDF) |
| 151 | Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock | 2.2 | 34 | Citations (PDF) |
| 152 | The number of discharge medications predicts thirty-day hospital readmission: a cohort study | 2.7 | 83 | Citations (PDF) |
| 153 | “Does this patient have…” “Is this patient at risk for infection with multidrug resistant bacteria?” | 5.3 | 9 | Citations (PDF) |
| 154 | 1233A Comparison of National Healthcare Safety Network (NHSN) Ventilator Associated Pneumonia (VAP) and Ventilator Associated Event (VAE) Definitions | 0.8 | 2 | Citations (PDF) |
| 155 | 1658C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients | 0.8 | 0 | Citations (PDF) |
| 156 | 881New Ventilator Associated Event (VAE) Definition: Persistence of Subjective Variability | 0.8 | 0 | Citations (PDF) |
| 157 | A randomized trial of real‐time automated clinical deterioration alerts sent to a rapid response team | 1.4 | 85 | Citations (PDF) |
| 158 | Treatment of gram - positive infections in critically ill patients | 2.7 | 35 | Citations (PDF) |
| 159 | Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival | 4.3 | 57 | Citations (PDF) |
| 160 | Rational Use of Antibiotics in the ICU | 7.3 | 26 | Citations (PDF) |
| 161 | Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study | 7.4 | 279 | Citations (PDF) |
| 162 | Reducing the Burden of Acute Respiratory Distress Syndrome | 2.4 | 21 | Citations (PDF) |
| 163 | Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa* | 0.6 | 182 | Citations (PDF) |
| 164 | Identifying Critically Ill Patients at Risk for Inappropriate Antibiotic Therapy | 0.6 | 21 | Citations (PDF) |
| 165 | Using the Number Needed to Treat to Assess Appropriate Antimicrobial Therapy as a Determinant of Outcome in Severe Sepsis and Septic Shock* | 0.6 | 107 | Citations (PDF) |
| 166 | Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department | 2.7 | 31 | Citations (PDF) |
| 167 | Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization | 7.4 | 10 | Citations (PDF) |
| 168 | Probiotics for preventing ventilator-associated pneumonia | 2.5 | 119 | Citations (PDF) |
| 169 | Effects of Empiric Antifungal Therapy for Septic Shock on Time to Appropriate Therapy for Candida Infection: A Pilot Study | 2.7 | 12 | Citations (PDF) |
| 170 | Candidemia and non-candidemia related septic shock: are there differences between them? | 5.3 | 3 | Citations (PDF) |
| 171 | Ventilator-Associated Pneumonia PreventionChest, 2014, 146, 873-874 | 0.5 | 4 | Citations (PDF) |
| 172 | If antibiotics did not exist | 5.3 | 2 | Citations (PDF) |
| 173 | Ventilator-associated Complications, Including Infection-related Complications | 2.3 | 22 | Citations (PDF) |
| 174 | A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia | 2.7 | 73 | Citations (PDF) |
| 175 | Determinants of Hospital Mortality Among Patients with Sepsis or Septic Shock Receiving Appropriate Antibiotic Treatment | 2.8 | 12 | Citations (PDF) |
| 176 | Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study | 2.3 | 45 | Citations (PDF) |
| 177 | Azithromycin and survival in<i>Streptococcus pneumoniae</i>pneumonia: a retrospective study | 2.0 | 12 | Citations (PDF) |
| 178 | Aerosolized antibiotics | 3.6 | 46 | Citations (PDF) |
| 179 | Developing a New, National Approach to Surveillance for Ventilator-Associated Events* | 0.6 | 643 | Citations (PDF) |
| 180 | Readmission Following Hospitalization for Pneumonia: The Impact of Pneumonia Type and Its Implication for Hospitals | 5.6 | 51 | Citations (PDF) |
| 181 | Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary | 5.6 | 58 | Citations (PDF) |
| 182 | Fluid balance and cardiac function in septic shock as predictors of hospital mortality | 7.4 | 134 | Citations (PDF) |
| 183 | Ventilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia | 0.5 | 3 | Citations (PDF) |
| 184 | Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated PneumoniaChest, 2013, 144, 1759-1767 | 0.5 | 139 | Citations (PDF) |
| 185 | Probiotics for Ventilator-Associated PneumoniaChest, 2013, 143, 590-592 | 0.5 | 4 | Citations (PDF) |
| 186 | What can be expected from antimicrobial de-escalation in the critically ill? | 5.3 | 16 | Citations (PDF) |
| 187 | Preventive Strategies in VAP: Focus on Silver-Coated Endotracheal Tubes 2013, , 531-555 | | 2 | Citations (PDF) |
| 188 | Appropriate Empirical Antibacterial Therapy for Nosocomial InfectionsDrugs, 2012, 63, 2157-2168 | 9.1 | 56 | Citations (PDF) |
| 189 | The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections | 9.1 | 728 | Citations (PDF) |
| 190 | Patients Hospitalized With Pneumonia: Determining the Need for Broad-Spectrum Antibiotic Therapy | 5.6 | 6 | Citations (PDF) |
| 191 | Validation of a Clinical Score for Assessing the Risk of Resistant Pathogens in Patients With Pneumonia Presenting to the Emergency Department | 5.6 | 154 | Citations (PDF) |
| 192 | Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control | 5.6 | 426 | Citations (PDF) |
| 193 | A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria* | 0.6 | 119 | Citations (PDF) |
| 194 | The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment* | 0.6 | 74 | Citations (PDF) |
| 195 | Prevention of ventilator-associated pneumonia or ventilator-associated complications | 0.6 | 33 | Citations (PDF) |
| 196 | Antimicrobial stewardship programs: mandatory for all ICUs | 7.4 | 37 | Citations (PDF) |
| 197 | A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia | 7.4 | 192 | Citations (PDF) |
| 198 | Risk Factors for Mixed Complicated Skin and Skin Structure Infections To Help Tailor Appropriate Empiric Therapy | 1.3 | 11 | Citations (PDF) |
| 199 | Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort | 2.3 | 339 | Citations (PDF) |
| 200 | Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study | 5.6 | 539 | Citations (PDF) |
| 201 | An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis | 2.7 | 36 | Citations (PDF) |
| 202 | Hospital-Acquired Pneumonia 2012, , 137-145 | | 1 | Citations (PDF) |
| 203 | Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens | 5.6 | 245 | Citations (PDF) |
| 204 | Healthcare-Associated Pneumonia: Approach to Management | 3.8 | 8 | Citations (PDF) |
| 205 | Medical Data Mining for Early Deterioration Warning in General Hospital Wards 2011, , 1042-1049 | | 26 | Citations (PDF) |
| 206 | Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia | 2.3 | 59 | Citations (PDF) |
| 207 | Implementation of a real-time computerized sepsis alert in nonintensive care unit patients* | 0.6 | 159 | Citations (PDF) |
| 208 | Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis* | 0.6 | 90 | Citations (PDF) |
| 209 | Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay* | 0.6 | 174 | Citations (PDF) |
| 210 | Health Care-Associated Pneumonia (HCAP) | 1.3 | 42 | Citations (PDF) |
| 211 | Hospital-acquired pneumonia/ventilator-associated pneumonia prevention: Truth or dare!* | 0.6 | 0 | Citations (PDF) |
| 212 | Clostridium difficile in the ICUChest, 2011, 140, 1643-1653 | 0.5 | 70 | Citations (PDF) |
| 213 | Ventilator-Associated Tracheobronchitis in a Mixed Surgical and Medical ICU PopulationChest, 2011, 139, 513-518 | 0.5 | 86 | Citations (PDF) |
| 214 | Institutional Perspective on the Impact of Positive Blood Cultures on the Economic and Clinical Outcomes of Patients With Complicated Skin and Skin Structure Infections: Focus on Gram-Positive Infections | 2.7 | 2 | Citations (PDF) |
| 215 | Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: A multicenter cohort study | 2.9 | 93 | Citations (PDF) |
| 216 | Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram‐negative bacteremia | 1.4 | 65 | Citations (PDF) |
| 217 | Antibiotic Stewardship in the Intensive Care Unit | 2.3 | 44 | Citations (PDF) |
| 218 | Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections–Proceedings and Data From the Gram-Negative Resistance Summit | 5.6 | 91 | Citations (PDF) |
| 219 | Prevention of Nosocomial Pneumonia in the Intensive Care Unit: Beyond the Use of Bundles | 1.3 | 24 | Citations (PDF) |
| 220 | Early Deterioration Warning for Hospitalized Patients by Mining Clinical Data | 0.7 | 6 | Citations (PDF) |
| 221 | Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation* | 0.6 | 62 | Citations (PDF) |
| 222 | Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation | 0.6 | 71 | Citations (PDF) |
| 223 | Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment | 0.6 | 66 | Citations (PDF) |
| 224 | A Comparison of Culture-Positive and Culture-Negative Health-Care-Associated PneumoniaChest, 2010, 137, 1130-1137 | 0.5 | 91 | Citations (PDF) |
| 225 | A magic bullet for sepsis: Getting back to the basics* | 0.6 | 0 | Citations (PDF) |
| 226 | The Resuscitation Package in Sepsis | 2.8 | 1 | Citations (PDF) |
| 227 | Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia | 3.2 | 84 | Citations (PDF) |
| 228 | Hospitalizations with healthcare‐associated complicated skin and skin structure infections: Impact of inappropriate empiric therapy on outcomes | 1.4 | 43 | Citations (PDF) |
| 229 | Probiotic Prophylaxis of Ventilator-associated Pneumonia | 9.3 | 326 | Citations (PDF) |
| 230 | Review of Recent Clinical Trials of Hospital‐Acquired Pneumonia and Ventilator‐Associated Pneumonia: A Perspective from Academia | 5.6 | 21 | Citations (PDF) |
| 231 | Methicillin-Resistant<i>Staphylococcus aureus</i>(MRSA) Nasal Colonization Predicts Intensive Care Unit-Acquired MRSA Infections: True Or False? | 1.3 | 7 | Citations (PDF) |
| 232 | Association Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients With Ventilator-Associated PneumoniaChest, 2010, 137, 1015-1021 | 0.5 | 65 | Citations (PDF) |
| 233 | Increased Mortality in Patients Without Ventilator-Associated Pneumonia: Response | 0.5 | 3 | Citations (PDF) |
| 234 | Health Care-Associated Pneumonia | 1.0 | 4 | Citations (PDF) |
| 235 | Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource
Utilization | 2.3 | 111 | Citations (PDF) |
| 236 | <i>Staphylococcus aureus</i>Nasal Colonization and Subsequent Infection in Intensive Care Unit Patients: Does Methicillin Resistance Matter? | 2.3 | 93 | Citations (PDF) |
| 237 | Predicting Bacteremia among Patients Hospitalized for Skin and Skin-Structure Infections: Derivation and Validation of a Risk Score | 2.3 | 30 | Citations (PDF) |
| 238 | Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators | 7.4 | 10 | Citations (PDF) |
| 239 | Will procalcitonin reduce antibiotic use in intensive care? | 14.8 | 10 | Citations (PDF) |
| 240 | Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis | 4.3 | 237 | Citations (PDF) |
| 241 | Bacteremia Increases the Risk of Death among Patients with Soft-Tissue Infections | 1.3 | 15 | Citations (PDF) |
| 242 | Health-Care-Associated PneumoniaChest, 2009, 135, 594-596 | 0.5 | 4 | Citations (PDF) |
| 243 | The Importance of Fluid Management in Acute Lung Injury Secondary to Septic ShockChest, 2009, 136, 102-109 | 0.5 | 452 | Citations (PDF) |
| 244 | Clinical Practice Improvement InitiativesChest, 2009, 136, 335-338 | 0.5 | 5 | Citations (PDF) |
| 245 | The Flood and Ebb of Septic Shock: ResponseChest, 2009, 136, 1705-1706 | 0.5 | 0 | Citations (PDF) |
| 246 | The Alphabet Soup of Pneumonia: CAP, HAP, HCAP, NHAP, and VAP | 2.3 | 63 | Citations (PDF) |
| 247 | Severe hospital-acquired pneumonia: A review for clinicians | 2.8 | 8 | Citations (PDF) |
| 248 | Candidemia on presentation to the hospital: development and validation of a risk score | 7.4 | 37 | Citations (PDF) |
| 249 | Diagnostic Implications of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in BAL Fluid of Patients With Pulmonary Infiltrates in the ICUChest, 2009, 135, 641-647 | 0.5 | 76 | Citations (PDF) |
| 250 | Preface | 3.6 | 1 | Citations (PDF) |
| 251 | Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia | 2.3 | 71 | Citations (PDF) |
| 252 | Epidemiology and Outcomes of Hospitalizations with Complicated Skin and Skin-Structure Infections: Implications of Healthcare-Associated Infection Risk Factors | 2.3 | 52 | Citations (PDF) |
| 253 | Implementing quality improvements in the intensive care unit: Ventilator bundle as an example | 0.6 | 86 | Citations (PDF) |
| 254 | Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis* | 0.6 | 105 | Citations (PDF) |
| 255 | Oral Decontamination to Prevent Ventilator-Associated PneumoniaChest, 2009, 135, 1116-1118 | 0.5 | 10 | Citations (PDF) |
| 256 | VAT vs VAPChest, 2009, 135, 252-255 | 0.5 | 12 | Citations (PDF) |
| 257 | Epidemiology and Outcomes of Clostridium difficile -Associated Disease Among Patients on Prolonged Acute Mechanical VentilationChest, 2009, 136, 752-758 | 0.5 | 46 | Citations (PDF) |
| 258 | Soluble Triggering Receptor Expressed on Myeloid Cells 1 and the Diagnosis of Ventilator-Associated Pneumonia: Response | 0.5 | 3 | Citations (PDF) |
| 259 | Health care–associated pneumonia: identification and initial management in the ED | 1.5 | 113 | Citations (PDF) |
| 260 | Secular Trends in Candidemia-Related Hospitalization in the United States, 2000–2005 | 2.3 | 129 | Citations (PDF) |
| 261 | Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia | 7.3 | 431 | Citations (PDF) |
| 262 | Introduction: Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections | 5.6 | 10 | Citations (PDF) |
| 263 | Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated PneumoniaChest, 2008, 134, 963-968 | 0.5 | 137 | Citations (PDF) |
| 264 | Health Care–Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes—Proceedings of the HCAP Summit | 5.6 | 112 | Citations (PDF) |
| 265 | Pneumonia Caused by Methicillin‐Resistant<i>Staphylococcus aureus</i> | 5.6 | 313 | Citations (PDF) |
| 266 | Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front | 5.6 | 232 | Citations (PDF) |
| 267 | Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for Health Care–Associated Pneumonia | 4.4 | 200 | Citations (PDF) |
| 268 | Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit | 5.6 | 56 | Citations (PDF) |
| 269 | SMART Approaches for Reducing Nosocomial Infections in the ICUChest, 2008, 134, 447-456 | 0.5 | 40 | Citations (PDF) |
| 270 | Predictors of 30-Day Mortality and Hospital Costs in Patients With Ventilator-Associated Pneumonia Attributed to Potentially Antibiotic-Resistant Gram-Negative BacteriaChest, 2008, 134, 281-287 | 0.5 | 252 | Citations (PDF) |
| 271 | A 50-Year-Old Woman With Abdominal Pain and Respiratory Failure 3 Months After Kidney TransplantationChest, 2008, 134, 442-446 | 0.5 | 16 | Citations (PDF) |
| 272 | The Modified APACHE II Score Outperforms Curb65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin-Resistant Staphylococcus aureus PneumoniaChest, 2008, 133, 363-369 | 0.5 | 39 | Citations (PDF) |
| 273 | The Importance of Early Treatment With Doxycycline in Human Ehrlichiosis | 1.3 | 67 | Citations (PDF) |
| 274 | Inappropriate therapy for methicillin-resistant Staphylococcus aureus: Resource utilization and cost implications* | 0.6 | 73 | Citations (PDF) |
| 275 | Treatment-related risk factors for hospital mortality in Candida bloodstream infections* | 0.6 | 167 | Citations (PDF) |
| 276 | Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience | 4.3 | 378 | Citations (PDF) |
| 277 | Bugging the Bugs: Novel Approaches in the Strategic Management of Resistant Staphylococcus aureus Infections | 5.6 | 2 | Citations (PDF) |
| 278 | Optimizing Therapy for MRSA Pneumonia | 2.3 | 8 | Citations (PDF) |
| 279 | Addition of Vasopressin to Norepinephrine as Independent Predictor of Mortality in Patients with Refractory Septic Shock: An Observational Study | 1.3 | 20 | Citations (PDF) |
| 280 | Moving Towards Real-Time Antimicrobial Management of Ventilator-Associated Pneumonia | 5.6 | 19 | Citations (PDF) |
| 281 | Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections | 5.6 | 166 | Citations (PDF) |
| 282 | Probiotics for Preventing and Treating Nosocomial InfectionsChest, 2007, 132, 286-294 | 0.5 | 55 | Citations (PDF) |
| 283 | Correctly scoring infections: CSI in the ICU* | 0.6 | 0 | Citations (PDF) |
| 284 | Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia | 0.6 | 119 | Citations (PDF) |
| 285 | Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?* | 0.6 | 731 | Citations (PDF) |
| 286 | A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia | 2.7 | 313 | Citations (PDF) |
| 287 | Use of Hypochlorite Solution to Decrease Rates of Clostridium difficile-Associated Diarrhea | 2.3 | 66 | Citations (PDF) |
| 288 | Predictors of In-Hospital Mortality for Bloodstream Infections Caused byEnterobacterSpecies orCitrobacter freundii | 3.2 | 41 | Citations (PDF) |
| 289 | Early Appropriate Empiric Therapy and Antimicrobial De-Escalation | 0.0 | 0 | Citations (PDF) |
| 290 | The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance | 1.3 | 5 | Citations (PDF) |
| 291 | Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia | 7.4 | 124 | Citations (PDF) |
| 292 | Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? | 3.6 | 63 | Citations (PDF) |
| 293 | Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated PneumoniaChest, 2006, 129, 1210-1218 | 0.5 | 356 | Citations (PDF) |
| 294 | Time To Get Serious About Infection Prevention in the ICUChest, 2006, 130, 1293-1296 | 0.5 | 14 | Citations (PDF) |
| 295 | Before–after study of a standardized hospital order set for the management of septic shock* | 0.6 | 424 | Citations (PDF) |
| 296 | Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment* | 0.6 | 141 | Citations (PDF) |
| 297 | Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study* | 0.6 | 150 | Citations (PDF) |
| 298 | Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy | 0.6 | 132 | Citations (PDF) |
| 299 | Providing appropriate antimicrobial therapy in the intensive care unit: Surveillance vs. de-escalation* | 0.6 | 34 | Citations (PDF) |
| 300 | Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database* | 0.6 | 278 | Citations (PDF) |
| 301 | Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care–Associated PneumoniaChest, 2006, 130, 947-955 | 0.5 | 244 | Citations (PDF) |
| 302 | Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia | 3.2 | 27 | Citations (PDF) |
| 303 | Microbiological Diagnosis of Ventilator-associated Pneumonia | 9.3 | 13 | Citations (PDF) |
| 304 | Diagnosis of Ventilator-Associated Pneumonia | 25.1 | 61 | Citations (PDF) |
| 305 | Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit? | 5.6 | 83 | Citations (PDF) |
| 306 | A Randomized Double-Blind Trial of Iseganan in Prevention of Ventilator-associated Pneumonia | 9.3 | 122 | Citations (PDF) |
| 307 | Prevention of nosocomial respiratory infections 2006, , 675-693 | | 0 | Citations (PDF) |
| 308 | Strategies to prevent antimicrobial resistance in the intensive care unit | 0.6 | 130 | Citations (PDF) |
| 309 | Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis | 0.6 | 223 | Citations (PDF) |
| 310 | Pleuropulmonary Complications of Panton-Valentine Leukocidin-Positive Community-Acquired Methicillin-Resistant Staphylococcus aureusChest, 2005, 128, 2732-2738 | 0.5 | 184 | Citations (PDF) |
| 311 | Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture ResultsChest, 2005, 128, 2706-2713 | 0.5 | 111 | Citations (PDF) |
| 312 | Prevention of hospital infection | 2.4 | 10 | Citations (PDF) |
| 313 | The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia | 0.3 | 2 | Citations (PDF) |
| 314 | Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa (activated) | 3.2 | 39 | Citations (PDF) |
| 315 | <i>Pseudomonas aeruginosa</i>Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment | 4.3 | 501 | Citations (PDF) |
| 316 | Quinolones for Treatment of Nosocomial Pneumonia: A Meta-Analysis | 5.6 | 24 | Citations (PDF) |
| 317 | Epidemiology and Outcomes of Health-care–Associated PneumoniaChest, 2005, 128, 3854-3862 | 0.5 | 964 | Citations (PDF) |
| 318 | Transfusion Practice and Blood Stream Infections in Critically Ill PatientsChest, 2005, 127, 1722-1728 | 0.5 | 118 | Citations (PDF) |
| 319 | Prevention of Pneumonia in the Hospital Setting | 3.8 | 4 | Citations (PDF) |
| 320 | Gram-Negative Bacterial Resistance: Evolving Patterns and Treatment Paradigms | 5.6 | 35 | Citations (PDF) |
| 321 | Delaying the Empiric Treatment of
<i>Candida</i>
Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality | 4.3 | 1,262 | Citations (PDF) |
| 322 | Title is missing! | 7.4 | 24 | Citations (PDF) |
| 323 | Risk Factors for Ventilator‐Associated Pneumonia: From Epidemiology to Patient Management | 5.6 | 265 | Citations (PDF) |
| 324 | Hospital Mortality for Patients With Bacteremia Due to Staphylococcus aureus or Pseudomonas aeruginosaChest, 2004, 125, 607-616 | 0.5 | 167 | Citations (PDF) |
| 325 | Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | 5.3 | 303 | Citations (PDF) |
| 326 | A Cost-Benefit Analysis of Gown Use in Controlling Vancomycin-ResistantEnterococcusTransmission Is It Worth the Price? | 2.3 | 71 | Citations (PDF) |
| 327 | Red blood cell transfusion and ventilator-associated pneumonia: A potential link? | 0.6 | 209 | Citations (PDF) |
| 328 | Prevention of hospital-associated pneumonia and ventilator-associated pneumonia | 0.6 | 379 | Citations (PDF) |
| 329 | Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients | 0.6 | 105 | Citations (PDF) |
| 330 | A Randomized Controlled Trial of an Antibiotic Discontinuation Policy for Clinically Suspected Ventilator-Associated PneumoniaChest, 2004, 125, 1791-1799 | 0.5 | 357 | Citations (PDF) |
| 331 | The Effect of an Education Program on the Incidence of Central Venous Catheter-Associated Bloodstream Infection in a Medical ICUChest, 2004, 126, 1612-1618 | 0.5 | 235 | Citations (PDF) |
| 332 | An Educational Intervention to Reduce Ventilator-Associated Pneumonia in an Integrated Health SystemChest, 2004, 125, 2224-2231 | 0.5 | 210 | Citations (PDF) |
| 333 | Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate | 5.3 | 32 | Citations (PDF) |
| 334 | Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions | 3.2 | 16 | Citations (PDF) |
| 335 | Ventilator-Associated Pneumonia in a Multi-Hospital System Differences in Microbiology by Location | 2.3 | 71 | Citations (PDF) |
| 336 | The importance of appropriate initial antibiotic therapy for hospital-acquired infections | 1.9 | 98 | Citations (PDF) |
| 337 | Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia | 2.7 | 229 | Citations (PDF) |
| 338 | Linezolid vs Vancomycin *Chest, 2003, 124, 1789-1797 | 0.5 | 598 | Citations (PDF) |
| 339 | Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia* | 0.6 | 154 | Citations (PDF) |
| 340 | Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center* | 0.6 | 525 | Citations (PDF) |
| 341 | Selective Digestive Decontamination Should Not Be Routinely Employed*Chest, 2003, 123, 464S-468S | 0.5 | 100 | Citations (PDF) |
| 342 | Improving Family Communications at the End of Life: Implications for Length of Stay in the Intensive Care Unit and Resource Use | 1.2 | 159 | Citations (PDF) |
| 343 | Why Do Physicians Not Follow Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia?Chest, 2002, 122, 656-661 | 0.5 | 224 | Citations (PDF) |
| 344 | Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US DatabaseChest, 2002, 122, 2115-2121 | 0.5 | 1,138 | Citations (PDF) |
| 345 | Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia* | 0.6 | 288 | Citations (PDF) |
| 346 | Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated PneumoniaChest, 2002, 122, 262-268 | 0.5 | 938 | Citations (PDF) |
| 347 | Silver-Coated Endotracheal Tubes Associated With Reduced Bacterial Burden in the Lungs of Mechanically Ventilated DogsChest, 2002, 121, 863-870 | 0.5 | 178 | Citations (PDF) |
| 348 | Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial | 3.3 | 285 | Citations (PDF) |
| 349 | Prevention of Antibiotic Resistance in Hospitals | 8.9 | 0 | Citations (PDF) |
| 350 | Antibiotic Resistance in the Intensive Care Unit | 8.9 | 398 | Citations (PDF) |
| 351 | Experience with a clinical guideline for the treatment of ventilator-associated pneumonia | 0.6 | 543 | Citations (PDF) |
| 352 | Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care ProfessionalsChest, 2001, 120, 454S-463S | 0.5 | 251 | Citations (PDF) |
| 353 | The Occurrence of Ventilator-Associated Pneumonia in a Community HospitalChest, 2001, 120, 555-561 | 0.5 | 318 | Citations (PDF) |
| 354 | A Comparative Analysis of Patients With Early-Onset vs Late-Onset Nosocomial Pneumonia in the ICU SettingChest, 2000, 117, 1434-1442 | 0.5 | 266 | Citations (PDF) |
| 355 | Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices | 0.6 | 159 | Citations (PDF) |
| 356 | Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients | 5.6 | 578 | Citations (PDF) |
| 357 | The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU SettingChest, 2000, 118, 146-155 | 0.5 | 1,683 | Citations (PDF) |
| 358 | Inadequate Antimicrobial Treatment of InfectionsChest, 1999, 115, 462-474 | 0.5 | 1,793 | Citations (PDF) |
| 359 | The Prevention of Ventilator-Associated Pneumonia | 25.1 | 517 | Citations (PDF) |
| 360 | A Randomized Clinical Trial of Continuous Aspiration of Subglottic Secretions in Cardiac Surgery PatientsChest, 1999, 116, 1339-1346 | 0.5 | 322 | Citations (PDF) |
| 361 | Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation | 0.6 | 1,064 | Citations (PDF) |
| 362 | The Influence of Mini-BAL Cultures on Patient OutcomesChest, 1998, 113, 412-420 | 0.5 | 531 | Citations (PDF) |
| 363 | A Randomized Clinical Trial Comparing an Extended-Use Hygroscopic Condenser Humidifier With Heated-Water Humidification in Mechanically Ventilated PatientsChest, 1998, 113, 759-767 | 0.5 | 392 | Citations (PDF) |
| 364 | High levels of C-reactive protein and positive troponin T test results predicted 14-day mortality in unstable angina or non-Q-wave MI | 0.1 | 0 | Citations (PDF) |
| 365 | A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation | 0.6 | 766 | Citations (PDF) |
| 366 | The Safety and Diagnostic Accuracy of Minibronchoalveolar Lavage in Patients with Suspected Ventilator-Associated Pneumonia | 8.9 | 195 | Citations (PDF) |
| 367 | The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient MortalityChest, 1995, 108, 1655-1662 | 0.5 | 385 | Citations (PDF) |
| 368 | Mechanical Ventilation with or without 7-Day Circuit Changes | 8.9 | 156 | Citations (PDF) |
| 369 | Preface | 2.3 | 1 | Citations (PDF) |
| 370 | Ventilator-Associated Pneumonia | 7.3 | 557 | Citations (PDF) |
| 371 | A Persistent Left Lower Lobe Infiltrate and Chronic Cough Following Chest Wounds Sustained in Vietnam Twenty-Four Years Earlier | 1.0 | 0 | Citations (PDF) |
| 372 | Staphylococcal Pneumonia 0, , 444-454 | | 0 | Citations (PDF) |
